Ethinylestradiol

Generic Name: Ethinylestradiol

Brand Names: Afirmelle 28 Day, Alesse, Altavera 28 Day, Alyacen 1/35, Alyacen 7/7/7, Amethia 91 Day, Amethyst, Annovera, Apri 28 Day, Aranelle 28, Ashlyna 91 Day, Aubra 28 Day, Aurovela, Aurovela Fe, Aviane 28, Ayuna 28 Day Pack, Azurette 28 Day, Balcoltra 28 Day, Balziva 28 Day, Bekyree 28 Day, Beyaz 28 Day, Blisovi 21 Fe 1.5/30 28 Day Pack, Blisovi 21 Fe 1/20 28 Day Pack, Blisovi 24 Fe 1/20 28 Day, Brevicon, Briellyn 28 Day, Camrese 91 Day, Camreselo 91 Day, Caziant 28 Day, Cesia 28 Day, Charlotte 24 Fe Chewable 28 Day, Chateal 28 Day, Cléo -35, Cryselle 28, Cyclafem 1/35 28 Day, Cyclafem 7/7/7 28 Day, Cyestra-35, Cyonanz 28 Day, Cyred 28 Day, Dasetta 1/35 28 Day, Dasetta 7/7/7 28 Day, Daysee 91 Day, Delyla 28 Day, Diane, Dolishale 28 Day, Elinest 28 Day, Eluryng, Emoquette, Enilloring, Enpresse 28 Day, Enskyce 28 Day, Estarylla 28 Day, Evra, Falmina 28 Day, Fayosim 91 Day, Femcon Fe 28 Day, Femhrt 0.5/2.5 28 Day, Femynor 28 Day, Finzala 24 Fe Chewable 28 Day, Freya, Fyavolv, Gemmily 28 Day, Gianvi 28-day, Hailey 1.5/30 21 Day, Hailey 24 Fe 28 Day, Hailey Fe 1.5/30 28 Day, Hailey Fe 1/20 28 Day, Iclevia 91 Day, Indayo, Introvale 91 Day, Isibloom 28 Day, Jaimiess 91 Day, Jasmiel 28 Day, Jinteli, Jolessa 91 Day, Joyeaux 28 Day, Juleber 28 Day, Junel 1.5/30 21 Day, Junel 1/20 21 Day, Junel Fe 1.5/30 28 Day, Junel Fe 1/20 28 Day, Junel Fe 24 1/20 28 Day, Kaitlib Fe 28 Day, Kalliga, Kariva 28 Day, Kelnor 1/35 28 Day, Kelnor 1/50 28 Day, Kurvelo, Larin 1.5/30, Larin 1/20, Larin 24 Fe 1/20, Larin Fe 1.5/30, Larin Fe 1/20, Larissia 28 Day Pack, Layolis Fe 28, Leena 28 Day, Levonest 28 Day, Levora 0.15/30 28 Day, Lillow 28 Day, Linessa, Lo Loestrin Fe 28 Day, Lo Simpesse, Lo-zumandimine 28 Day, Lo/ovral 28 Day, LoJaimiess, Loestrin 1.5/30 21 Day, Loestrin 24 Fe 28 Day, Loestrin Fe 1/20 28 Day, Lolo, Lomedia 24 Fe, Loryna, Loseasonique, Low-ogestrel 28 Day, Lutera 28 Day, Marlissa 28 Day, Marvelon, Melodetta 24 Fe Chewable 28 Day, Merzee 28 Day, Mibelas 24 Fe Chewable 28 Day, Microgestin 1.5/30 21 Day, Microgestin 1/20 21 Day, Microgestin 24 Fe 28 Day, Microgestin Fe 1.5/30 28 Day, Microgestin Fe 1/20 28 Day, Mili 28 Day, Min-ovral, Minastrin 24 Fe Chewable 28 Day, Mircette 28 Day, Mono-linyah 28 Day, Mononessa 28 Day, Myzilra 28 Day, Necon 0.5/35 28 Day, Necon 1/35 28 Day, Necon 7/7/7 28 Day, Nexesta Fe 28 Day, Nikki 28 Day, Nortrel 1/35 21 Day, Nortrel 1/35 28 Day, Nortrel 7/7/7 28 Day, Nuvaring, Nylia 1/35 28 Day, Nylia 7/7/7 28 Day, Nymyo 28 Day, Ocella 28 Day, Orsythia 28 Day, Ortho Tri-cyclen 28 Day, Ortho Tri-cyclen Lo 28 Day, Ortho-novum 7/7/7 28 Day, Philith 28 Day, Pimtrea Pack, Pirmella 1/35 28 Day, Pirmella 7/7/7 28 Day, Portia 28 Day, Previfem 28 Day, Quartette 91 Day Pack, Reclipsen, Rhuzdah 28 Day, Rivelsa 91 Day, Safyral 28 Day, Seasonale, Seasonique, Select, Setlakin 91 Day, Simliya, Simpesse, Sprintec 28 Day, Sronyx 28 Day, Syeda 28 Day, Synphasic, Tarina 24 Fe 1/20 28 Day, Tarina Fe 1/20 28 Day, Taysofy 28 Day, Taytulla 28 Day, Tilia Fe, Tri Femynor 28 Day, Tri-LO- Estarylla 28 Day, Tri-LO-marzia 28-day, Tri-LO-mili, Tri-Lo-Sprintec, Tri-estarylla 28 Day, Tri-legest 28 Day, Tri-linyah, Tri-mili 28 Day, Tri-nymyo 28 Day Pack, Tri-previfem 28 Day, Tri-sprintec 28 Day, Tri-vylibra 28 Day, Tri-vylibra Lo 28 Day, Trinessa 28 Day, Trinessa Lo 28 Day, Triquilar, Trivora 28 Day, Turqoz 28 Day, Twirla 3 Count Weekly Patch, Tyblume 28 Day, Tydemy 28 Day, Velivet 28 Day, Vestura, Vienva 28 Day, Viorele 28 Day, Volnea 28 Day, Vyfemla 28 Day, Vylibra 28 Day, Wera 28 Day, Wymzya Fe 28 Day, Xulane, Yasmin, Yasmin 28 Day, Yaz 28 Day, Yaz Plus, Zafemy, Zarah, Zenchent, Zovia 1/35e 28 Day, Zovia 1/50e 28 Day, Zumandimine 28 Day

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₄O_₂

CAS Number: 57-63-6

Unique Ingredient Identifier: 423D2T571U

Background: Ethinylestradiol was first synthesized in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering. It was developed in an effort to create an estrogen with greater oral bioavailability. These properties were achieved by the substitution of an ethinyl group at carbon 17 of estradiol. Ethinylestradiol soon replaced mestranol in contraceptive pills.
...

Indication: Ethinylestradiol is combined with other drugs for use as a contraceptive, premenstrual dysphoric disorder, moderate acne, moderate to severe vasomotor symptoms of menopause, prevention of postmenopausal osteoporosis.

Associated Conditions: Menopausal Osteoporosis, Mild to Moderate Acne, Premenstrual Dysphoric Disorder (PMDD), Moderate Acne vulgaris, Moderate, severe, Vasomotor Symptoms caused by Menopause

Associated Therapies: Contraception, Folate supplementation therapy

Clinical Trials

A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese

Phase 1

Completed

Conditions: Overweight

Interventions: Drug: LY3437943
Drug: Ethinyl Estradiol
Drug: Drospirenone

First Posted Date: 2023-09-15

Last Posted Date: 2024-07-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 46

Registration Number: NCT06039826

Locations: 🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States

A Study of Milvexian in Healthy Adult Females

Phase 1

Completed

Conditions: Healthy Female

Interventions: Drug: Milvexian
Drug: Midazolam
Drug: Ethinylestradiol
Drug: Drospirenone

First Posted Date: 2023-01-31

Last Posted Date: 2023-08-18

Lead Sponsor: Janssen Pharmaceutica N.V., Belgium

Target Recruit Count: 20

Registration Number: NCT05706753

Locations: 🇧🇪
SGS Belgium NV, Edegem, Belgium

The Effect of Polycystic Ovary Syndrome Treatment on Metabolomics

Not Applicable

Conditions: Polycystic Ovary Syndrome

Interventions: Drug: Diane-35
Drug: Yasmin

First Posted Date: 2021-04-05

Last Posted Date: 2022-05-19

Lead Sponsor: Inonu University

Target Recruit Count: 42

Registration Number: NCT04831151

Locations: 🇹🇷
Inonu University, Malatya, Turkey

Efficacy of Dienogest Versus Oral Contraceptive Pills on Pain Associated With Endometriosis

Phase 2

Conditions: Endometriosis

Interventions: Drug: Dienogest 2 MG Oral Tablet
Drug: Yasmin

First Posted Date: 2020-02-05

Last Posted Date: 2021-04-15

Lead Sponsor: American University of Beirut Medical Center

Target Recruit Count: 100

Registration Number: NCT04256200

Locations: 🇱🇧
American University of Beirut, Beirut, Lebanon

Traditional Chinese Medicine, Western Medicine and Low-level Light Therapy（LLLT） for Primary Dysmenorrhea（PD）

Phase 4

Conditions: Primary Dysmenorrhea
Traditional Chinese Medicine
Light

Interventions: Drug: DING KUN DAN
Drug: Simulated drug of DING KUN DAN
Device: low level light therapy
Drug: Marvelon

First Posted Date: 2019-05-17

Last Posted Date: 2019-06-25

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 480

Registration Number: NCT03953716

Locations: 🇨🇳
Xiao MA, Beijing, Beijing, China

Continuous Versus Cyclical OCP Use in PCOS

Phase 4

Completed

Conditions: Polycystic Ovary Syndrome

Interventions: Drug: Yasmin

First Posted Date: 2019-01-28

Last Posted Date: 2023-01-10

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 60

Registration Number: NCT03819140

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri

Early Phase 1

Conditions: Adenomyosis

Interventions: Device: Metraplant-E
Drug: Yasmin

First Posted Date: 2017-01-31

Last Posted Date: 2017-01-31

Lead Sponsor: Ain Shams Maternity Hospital

Target Recruit Count: 32

Registration Number: NCT03037944

Locations: 🇪🇬
Ain Shams University - Maternity Hospital, Cairo, Egypt

A Study to Investigate the Effect of JNJ-63623872 at Steady-state on the Steady-state Pharmacokinetics of Ethinylestradiol and Norethindrone

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ethinylestradiol
Drug: Norethindrone
Drug: JNJ-63623872

First Posted Date: 2016-01-12

Last Posted Date: 2016-06-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 18

Registration Number: NCT02652650

Phlebotomy and Polycystic Ovary Syndrome

Not Applicable

Completed

Conditions: Metabolic Cardiovascular Syndrome
Hyperandrogenism

Interventions: Procedure: Phlebotomy
Drug: ethinylestradiol
Drug: Cyproterone Acetate

First Posted Date: 2015-06-02

Last Posted Date: 2022-07-27

Lead Sponsor: Manuel Luque Ramírez

Target Recruit Count: 37

Registration Number: NCT02460445

Locations: 🇪🇸
Diabetes, Obesity and Human Reproduction Research Group, Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain

Comparison Between Oral Contraceptive Pills and Calcium Supplements in Treatment of Premenstrual Syndrome

Phase 3

Completed

Conditions: Premenstrual Syndrome

Interventions: Drug: Placebo 1
Dietary Supplement: Calver
Drug: Yasmin
Drug: Placebo 2

First Posted Date: 2014-03-18

Last Posted Date: 2015-08-11

Lead Sponsor: Beni-Suef University

Target Recruit Count: 210

Registration Number: NCT02089620

Locations: 🇪🇬
Beni-Suef University, Beni-Suef, Egypt

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy